NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IPSC

Century Therapeutics Inc

Jul 03 • 04:00PM ET

0.5551

Dollar change +0.0001
Percentage change 0.02	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT NTLA BEAM DNLI ARCT SGMO VERV CARR ZNTL

| Held by: VTI VXF VTWO SCHA IWM VTWV IWN MSSM IWC IWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	52.88%	Shs Outstand	86.15M	Perf Week	-2.20%
Market Cap	47.83M	Forward P/E	-	EPS next Y	-1.35	Insider Trans	-0.18%	Shs Float	40.60M	Perf Month	-2.63%
Enterprise Value	-64.62M	PEG	-	EPS next Q	-0.38	Inst Own	28.81%	Short Float	5.70%	Perf Quarter	18.18%
Income	-21.95M	P/S	0.42	EPS this Y	82.97%	Inst Trans	-19.91%	Short Ratio	2.70	Perf Half Y	-44.49%
Sales	114.90M	P/B	0.20	EPS next Y	-393.84%	ROA	-6.61%	Short Interest	2.32M	Perf YTD	-45.04%
Book/sh	2.79	P/C	0.29	EPS next 5Y	5.86%	ROE	-10.49%	52W High	3.29 -83.13%	Perf Year	-76.97%
Cash/sh	1.92	P/FCF	-	EPS past 3/5Y	2.61% 18.46%	ROIC	-7.61%	52W Low	0.34 62.40%	Perf 3Y	-93.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	88.43%	Volatility	5.37% 6.30%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-0.56	EPS Y/Y TTM	87.23%	Oper. Margin	-26.04%	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.70	Sales Y/Y TTM	8286.79%	Profit Margin	-19.10%	RSI (14)	47.49	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	11.70	EPS Q/Q	297.38%	SMA20	-4.28%	Beta	1.78	Target Price	5.00
Payout	-	Debt/Eq	0.22	Sales Q/Q	12667.72%	SMA50	-0.39%	Rel Volume	0.25	Prev Close	0.56
Employees	150	LT Debt/Eq	0.20	Earnings	May 15 AMC	SMA200	-39.93%	Avg Volume	857.54K	Price	0.56
IPO	Jun 18, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	11510.26% 164.37%	Trades		Volume	214,228	Change	0.02%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Initiated	Rodman & Renshaw	Buy	$6
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral	$28 → $5
Dec-27-22	Initiated	Chardan Capital Markets	Buy	$19
Oct-31-22	Initiated	Guggenheim	Buy	$15
Oct-10-22	Initiated	Canaccord Genuity	Buy	$28
May-23-22	Initiated	H.C. Wainwright	Buy	$27
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	Piper Sandler	Overweight	$38
Jul-13-21	Initiated	JP Morgan	Overweight	$40
Jul-13-21	Initiated	BofA Securities	Buy	$34

Jun-25-25 08:50AM	Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Jun-06-25 08:50AM	Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain (Zacks) +9.47%
May-28-25 04:01PM	Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress (GlobeNewswire)
May-15-25 08:15PM	Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates (Zacks) +5.79% +8.23%
04:01PM	Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
05:10PM	Loading…
May-14-25 05:10PM	Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.02%
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 10:01AM	Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:20AM	Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-28-25 04:30PM	Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-15-25 04:01PM	Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 (GlobeNewswire)
Mar-25-25 12:00PM	Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-19-25 05:15PM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.66%
04:01PM	Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jan-21-25 07:00AM	Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders (GlobeNewswire)
07:00AM	Loading…
Nov-26-24 07:00AM	Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 12:00PM	What Makes Century Therapeutics (IPSC) a New Buy Stock (Zacks)
Nov-05-24 10:15AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
09:05AM	Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
09:00AM	Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-04-24 07:00AM	Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-26-24 07:00AM	Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer (GlobeNewswire)
Aug-08-24 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-09-24 12:00PM	Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-03-24 07:00AM	Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting (GlobeNewswire)
May-10-24 03:35PM	Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ... (GuruFocus.com)
07:00AM	Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting (GlobeNewswire)
May-09-24 01:54PM	IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:40AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Loading…
07:30AM	Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-23-24 07:00AM	Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-11-24 08:25AM	Century buys a startup, raises funding in cell therapy expansion (BioPharma Dive) +7.14%
07:00AM	Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics (GlobeNewswire)
Apr-08-24 04:05PM	Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.08%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) -9.48%
Mar-19-24 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Mar-14-24 01:52PM	IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.20%
07:30AM	Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-08-24 11:55PM	Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares (GuruFocus.com)
Mar-07-24 09:55AM	How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4% (Zacks) +6.30%
Mar-05-24 06:03PM	Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.65%
Feb-01-24 07:00AM	Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-09-23 12:00PM	Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits (GlobeNewswire)
Dec-07-23 11:01AM	Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study (Zacks) +8.37%
Dec-06-23 07:30AM	Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus (GlobeNewswire) +36.08%
07:30AM	Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-21-23 07:00AM	Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 03:58PM	FMR LLC Adjusts Position in Century Therapeutics Inc (GuruFocus.com)
Nov-09-23 08:29AM	Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results (GuruFocus.com) -13.13%
07:01AM	Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer (GlobeNewswire)
07:00AM	Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-02-23 09:00AM	Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits at the 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-26-23 07:00AM	Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-09-23 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-23 06:48AM	Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago (Simply Wall St.)
May-12-23 06:11AM	Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-17-23 07:00AM	Century Therapeutics to Present at Chardans 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit (GlobeNewswire)
Apr-12-23 08:30AM	Century Therapeutics Announces Leadership Changes (GlobeNewswire) -7.91%
Mar-16-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-15-23 04:01PM	Century Therapeutics to Present at the AACR Annual Meeting 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-23 07:30AM	Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas (GlobeNewswire)
Feb-01-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:35AM	After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC) (Zacks) -7.36%
Jan-09-23 10:46AM	Century Therapeutics becomes latest life sciences company to enact layoffs, narrow focus (American City Business Journals)
Jan-06-23 08:23AM	Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive (Benzinga)
Jan-05-23 04:01PM	Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire)
Jan-04-23 07:00AM	Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 10:02AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 12% this week, taking one-year losses to 39% (Simply Wall St.)
Nov-22-22 07:00AM	Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.24%
Nov-11-22 07:00AM	Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates (GlobeNewswire) -5.01%
Nov-10-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +15.11%
07:30AM	Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-02-22 07:05AM	Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022 (GlobeNewswire)
Oct-05-22 04:05PM	Century Therapeutics to Present at the SITC 37th Annual Meeting (GlobeNewswire)
Oct-03-22 07:00AM	Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors (GlobeNewswire)
Sep-26-22 07:00AM	Century Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-25-22 07:30AM	Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection (GlobeNewswire)
Aug-11-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-07-22 01:43PM	Century Therapeutics nearly tripling planned space at One uCity Square (American City Business Journals)
Jul-01-22 09:18AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 13% this week, taking one-year losses to 71% (Simply Wall St.)
Jun-24-22 04:30PM	Century Therapeutics Announces Its Addition to the Russell Microcap® Index (GlobeNewswire) -6.39% -8.37%
Jun-21-22 04:30PM	Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium (GlobeNewswire) +5.60%
Jun-06-22 07:30AM	Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022 (GlobeNewswire)
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-16-22 07:30AM	Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +9.79%
May-03-22 04:30PM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-22 04:30PM	Century Therapeutics to Present at the ASGCT 25th Annual Meeting (GlobeNewswire)
Apr-18-22 04:30PM	Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-06-22 04:30PM	Century Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-22 04:30PM	Century Therapeutics to Present at the H.C. Wainwright Gene Therapy and Gene Editing Conference (GlobeNewswire) +5.97%

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carr Douglas	SVP Finance & Operations	Jun 09 '25	Sale	0.62	4,904	3,050	405,982	Jun 11 05:05 PM
Farid Adrienne	Chief Operations Officer	Jun 09 '25	Sale	0.62	552	343	250,141	Jun 11 05:05 PM
Pfeiffenberger Brent	President and CEO	Jun 09 '25	Sale	0.62	475	295	1,681,783	Jun 11 05:05 PM
Russotti Gregory	See Remarks	Jun 09 '25	Sale	0.62	526	327	392,047	Jun 11 05:04 PM
Pfeiffenberger Brent	Officer	Jun 09 '25	Proposed Sale	0.62	475	296		Jun 09 03:15 PM
Farid Adrienne	Officer	Jun 09 '25	Proposed Sale	0.62	552	343		Jun 09 03:13 PM
Russotti Gregory	Officer	Jun 09 '25	Proposed Sale	0.62	526	327		Jun 09 03:09 PM
Pfeiffenberger Brent	President and CEO	May 16 '25	Sale	0.55	29,552	16,135	1,682,258	May 20 04:19 PM
Pfeiffenberger Brent	Officer	May 16 '25	Proposed Sale	0.55	29,552	16,138		May 16 03:47 PM
Farid Adrienne	Chief Operations Officer	May 05 '25	Sale	0.55	1,024	563	250,693	May 07 04:38 PM
Carr Douglas	SVP Finance & Operations	May 05 '25	Sale	0.55	295	162	410,886	May 07 04:38 PM
Farid Adrienne	Officer	May 05 '25	Proposed Sale	0.55	1,024	563		May 05 03:39 PM
Pfeiffenberger Brent	President and CEO	Mar 10 '25	Sale	0.61	2,235	1,375	1,190,310	Mar 12 07:30 PM
Russotti Gregory	See Remarks	Mar 10 '25	Sale	0.61	2,360	1,451	272,573	Mar 12 07:28 PM
Farid Adrienne	Chief Operations Officer	Mar 10 '25	Sale	0.61	2,359	1,451	131,717	Mar 12 07:27 PM
Carr Douglas	SVP Finance & Operations	Mar 10 '25	Sale	0.61	1,240	763	315,556	Mar 12 07:26 PM
Pfeiffenberger Brent	Officer	Mar 10 '25	Proposed Sale	0.62	2,235	1,375		Mar 10 04:21 PM
Russotti Gregory	Officer	Mar 10 '25	Proposed Sale	0.62	2,360	1,452		Mar 10 04:21 PM
Farid Adrienne	Officer	Mar 10 '25	Proposed Sale	0.62	2,359	1,451		Mar 10 04:17 PM
Pfeiffenberger Brent	President and CEO	Feb 18 '25	Sale	0.78	34,712	27,179	1,192,545	Feb 20 04:00 PM
Pfeiffenberger Brent	Officer	Feb 18 '25	Proposed Sale	0.78	34,712	27,166		Feb 18 04:10 PM
Farid Adrienne	Chief Operations Officer	Feb 03 '25	Sale	0.78	1,054	822	134,076	Feb 05 05:31 PM
Carr Douglas	SVP Finance & Operations	Feb 03 '25	Sale	0.78	351	274	316,796	Feb 05 05:30 PM
Farid Adrienne	Officer	Feb 03 '25	Proposed Sale	0.78	1,054	823		Feb 03 03:13 PM
Farid Adrienne	Chief Operations Officer	Nov 04 '24	Sale	1.23	1,033	1,267	135,130	Nov 05 04:59 PM
Carr Douglas	SVP Finance & Operations	Nov 04 '24	Sale	1.23	283	347	317,147	Nov 05 04:59 PM
Farid Adrienne	Officer	Nov 04 '24	Proposed Sale	1.23	1,033	1,268		Nov 04 03:52 PM
Quimi Daphne	Director	Sep 12 '24	Buy	1.53	5,000	7,657	5,000	Sep 16 04:18 PM
Farid Adrienne	Chief Operations Officer	Aug 05 '24	Sale	1.83	1,073	1,960	136,163	Aug 07 04:06 PM
Carr Douglas	SVP Finance & Operations	Aug 05 '24	Sale	1.83	289	528	334,041	Aug 07 04:06 PM
Farid Adrienne	Officer	Aug 05 '24	Proposed Sale	1.83	1,073	1,960		Aug 05 03:06 PM
Russotti Gregory	See Remarks	Jul 26 '24	Sale	2.50	586	1,465	274,933	Jul 31 09:08 AM
Russotti Gregory	Officer	Jul 26 '24	Proposed Sale	2.50	586	1,465		Jul 26 05:03 PM
Russotti Gregory	See Remarks	Jul 24 '24	Sale	2.52	1,600	4,029	275,519	Jul 25 05:04 PM
Russotti Gregory	See Remarks	Jul 23 '24	Sale	2.50	200	500	277,119	Jul 25 05:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IPSC

Century Therapeutics Inc

Upgrade your FINVIZ experience